CAR-T Cell Immunotherapy Overview
CAR-T Cell immunotherapy refers to a type of treatment in which a patient’s T cells are extracted using leukapheresis, then genetically altered in a laboratory, and given back to the patient through infusion. These are modified to attack cancer cells by adding genes to produce chimeric antigen receptors (CAR) that bind to certain proteins on the cancer cells, causing apoptosis. This type of therapy is typically used in blood cancers, such as advanced relapsed or refractory lymphomas, multiple myeloma or acute lymphoblastic leukemia (ALL). There are currently five approved CAR-T Cell options – Abecma ®, Breyanzi ®, KymriahTM, Tecartus ®, and YescartaTM.
Additional Information:
Product Comparison:
| Brand Name | Generic | Indication | Cost (WAC) |
| Abecma | Idecabtagene vicleucel (ide-cel) | Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) after 4 or more prior therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody. 5TH LINE | $420,000 |
| Breyanzi | Lisocabtagene maraleucel (liso-cel) | Treatment of relapsed or refractory large B-cell lymphoma in adults after >2 or lines of systemic therapy. Not indicated for the treatment of primary CNS lymphoma. | $410,000 |
| Kymriah | Tisagenleclecuel (tisa-cel) | Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse in patients up to 25 years of age. Treatment of relapsed or refractory large B-cell lymphoma in adults after > 2 or lines of systemic therapy. Not indicated for the treatment of primary CNS lymphoma. |
$475,000 |
| Tecartus | Brexucabtagene autoleucel (brexu-cel) | Treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults. | $373,000 |
| Yescarta | Axicabtagene ciloleucel (axi-cel) | Treatment of relapsed or refractory follicular lymphoma in adults after >2 lines of systemic therapy. Treatment of relapsed or refractory large B-cell lymphoma in adults after >2 lines of systemic therapy. Not indicated for the treatment of primary CNS lymphoma. | $373,000 |